Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment

International Heart Journal

Volumn 46, Issue 1, 2005, Pages 139-145

  Yang, Teng Yao ^a   Chang, Shi Tai ^a   Chung, Chang Ming ^a   Cheng, Nye Jan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

No reflow phenomenon; Percutaneous coronary intervention; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE; HEPARIN; ISOSORBIDE DINITRATE; PROPRANOLOL; TIROFIBAN; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; TYROSINE;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BALLOON DILATATION; BLOOD CLOT LYSIS; BLOOD PRESSURE MONITORING; CASE REPORT; CLINICAL FEATURE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE ASSOCIATION; DRUG EFFICACY; ELECTROCARDIOGRAM; ENZYME ANALYSIS; FOLLOW UP; HEART INFARCTION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; STENT; SYNDROME;

AGED; CORONARY CIRCULATION; CORONARY DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; SYNDROME; TYROSINE;

EID: 18944362962     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.139     Document Type: Article

References (17)

1. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994; 89: 2514-8.
2. Kenner MD, Zajac EJ, Kondos GF, et al. Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one-month follow up. Am J Cardiol 1995; 76: 861-8.
3. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105: 656-62. (Review)
4. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-9.
5. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995; 75: 778-82.
6. Sakata Y, Kodama K, Ishikura F, et al. Disappearance of the 'no-reflow' phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J 1997; 61: 455-8.
7. Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132: 959-63.
8. Feld H, Lichstein E, Schachter J, Shani J. Early and late angiographic findings of the "no-reflow" phenomenon following direct angioplasty as primary treatment for acute myocardial infarction. Am Heart J 1992; 123: 782-4.
9. Kloner RA, Alker K, Campbell C, Figures G, Eisenhauer, Hale S. Does tissue-type plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi? Circulation 1989; 79: 1125-36.
10. Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon. Chest 2002; 122: 1322-32.
11. Collet JP, Montalescot G, Lesty C, et al. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001; 103: 2328-31.
12. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echography study. J Am Coll Cardiol 2004; 43: 276-83.
13. Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P. Successful dissolution of cocclusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 1999; 48: 211-3.
14. Akdemir R, Uyan C. Dissolution of a huge spontaneous coronary artery thrombus with a new antiplatelet agent and coronary angioplasty. Int J Cardiol 2003; 89: 87-9.
15. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-control trial of platelet glycoprotein IIb/IIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98: 734-41.
16. Stone GW, Grines CL, Cox DA, et al. A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction-primary endpoint analysis from the CADILLAC trial [abstract]. Circulation 2000; 102(suppl II): II-664.
17. Yip HK, Wu CJ, Chang HW, et al. Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes. Chest 2003; 124: 962-8.